US-based biotech firm Indaptus Therapeutics, Inc. has secured new patent approvals in China, Japan and Israel for its De...
Amid intensifying U.S.-China trade tensions, Beijing has escalated its retaliatory measures by banning U.S. biot...
Japan-headquartered Olympus, a global medical technology company committed to making people's lives healthier, safer and...
Callio Therapeutics, a Singapore and US-based biotechnology startup focused on realising the promise of multi-payload an...
Degrader-antibody conjugates (DACs) represent a natural evolution in targeted precision medicines for oncology and other...
Can you share how the company’s focus has evolved since its founding, and what areas are central to Terumo's curre...
Soon after being sworn in as the 47th President of the United States, Donald Trump signed an Executive Order to withdraw...
This formal agreement establishes a collaborative framework between two like-minded, full-service Contract Res...
“We made good progress in 2024, which was capped by a fourth quarter of strong topline growth driven by key produc...
"Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance glob...
US-based startup HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by China-based Harb...
For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc, a global leader ...
Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufactur...
US-based Parse Biosciences, the leader in high-throughput single cell sequencing, has announced the launch of Evercode W...
"This transition is a testament to our commitment to both continuity and innovation," announced Merck KGaA, Darmstadt, G...
NEC Orchestrating Future Fund, an ecosystem-based corporate venture capital (CVC) fund, has invested in Aetion, Inc., a ...
Pfizer reported a strong fourth quarter (Q4) of 2024, achieving $17.8 billion in total revenues, reflecting a 21% year-o...
Novartis delivered a strong Q4 2024 performance, with net sales growing by 16% year-over-year (YoY) at constant currency...
